Drug Profile
DCB MB1
Alternative Names: DCB-MB1Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Rheumatoid arthritis in Taiwan (unspecified route), prior to August 2023 (Development Center for Biotechnology website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Taiwan
- 18 Jan 2016 Preclinical trials in Rheumatoid arthritis in Taiwan (unspecified route)